Medicon Valley Academy and Norgenta North German Life Science Agency agree on cooperation in two projects
The aim of the project is to facilitate academic institutions to work on therapeutic molecules according to industrial standards and on industrial scale. The Medicon Valley Academy will support the project partners in winning academic institutions from the Øresund region for this European project. "With this agreement we will pave the way for integrating the expertise of the Øresund region's first-class research facilities into the LinkUp project" stresses Dr. Kathrin Adlkofer, Norgenta's managing director, subsequent to signing the agreement. Prof. Per Belfrage, Chairman of the Medicon Valley Academy Board, appreciates the cooperation. "The cooperation with Norgenta will, due to this agreement, be started with two already concrete projects being very important for both regions."
The second project is the application of the Øresund region as hosting region of the Innovative Medicine Initiative (IMI) secretariat, an initiative presented by the European Union together with the EFPIA (European Federation of Pharmaceutical Industry and Associations). IMI is a European technology platform aiming not only at the faster development of safe and effective drugs. It also aims at the revitalisation of the European Scientific Community in the field of Biomedicals.
Medicon Valley Academy and Norgenta have, due to their commitment in the meta network ScanBalt, a considerable interest to settle this secretariat within the ScanBalt region. In future, both regions will exchange information concerning important projects and aim at cooperating beyond these first two concrete projects.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.